Company Updates
Private Credit Is No Longer Just a Defensive Play. Here Is What Investors Actually Want.
Private credit is no longer just a defensive allocation. Based on our 2026 Investor Survey, the largest segment of investors (44%) now wants hybrid structures that combine yield with equity optionality, demanding that fund managers rethink how credit products are structured, positioned, and sold.
Where Capital Is Flowing in 2026: What Active Investors Told Us About the Sectors That Matter
Every year, we survey our investor network. Not to confirm what we already think, but to understand what is actually driving capital allocation decisions across the sophisticated investor community. This year, the results were striking. Not because they were surprising, but because of how precisely they align with the macro research now emerging from some […]
Forget antibiotics: Why the next big medical breakthrough is a beam of light
Lindo Life Science, founded by Robert Gangi, is changing the battle against antimicrobial resistance (AMR) with the Lindo Tube, which uses occupant-safe antimicrobial blue light to shatter 99.9% of bacteria. This breakthrough prevents Ventilator-Associated Pneumonia (VAP), a secondary infection affecting nearly one in four intubated patients, and has been validated by a collaboration with the Mayo Clinic.
Inside the Australian Life Sciences Boom: Renowned Investors, World-Class Partners, World-Leading Breakthroughs
The Australian life sciences sector is experiencing an unprecedented boom, marked by world-leading partnerships, rapid regulatory progress, and significant capital investment. The Emergence Preview Series showcased companies with technologies already in clinical trials and backed by renowned global institutions and investors. This moment feels different due to the maturity and global reach of Australian life sciences innovation.
The 2026 Family Office Briefing: The Great Professionalisation
The days of the family office as a “cottage industry” are over. As complexity overtakes capital, ultra-wealthy families are rapidly professionalising, shifting their focus to direct private markets, integrating AI as an operating system, and hiring non-family, institutional talent. Discover the four strategic imperatives—from navigating the $124 trillion succession crisis to adopting new governance frameworks—that are driving this era of Family Office Professionalisation in 2026.
Wholesale Investor and MTPConnect Announce Strategic Partnership to Accelerate Investment in Australia’s Life Sciences Sector
Wholesale Investor and MTPConnect announce a landmark strategic partnership to bridge the funding gap in Australia’s life sciences sector. The collaboration creates a comprehensive capital engagement program, culminating in the Life Sciences Investor Day at the Emergence 2026 Conference
Steve Torso on Why Brevity Wins in Capital Raising
In the relentless pursuit of investment, founders often believe more information equates to more persuasion. However, according to Steve Torso, Co-founder and Managing Director at CapitalHQ and Wholesale Investor, the science of successful capital raising dictates a counter-intuitive approach: less is more, especially in the initial stages. “When you’re actually communicating your business, you’ve got […]
Wholesale Investor and CapitalHQ Sign Exclusive Master Licence with inQ Innovation Global to Provide Access to India’s High-Growth Startup Market
Wholesale Investor and inQ Innovation have forged a strategic partnership, granting global investors direct access to India’s rapidly expanding innovation ecosystem. This exclusive three-year agreement leverages CapitalHQ’s technology to streamline fundraising for Indian startups and expand deal flow for WI’s 45,000-strong investor network, aligning with India’s 2030 Vision for economic growth and innovation.
EBR Systems: Aussie Medtech Ready to Disrupt $3.6B Heart Failure Market with Leadless Pacemaker
Andrew Shute, Senior Vice President of Business Development at EBR Systems, is confident that his Australian medical device company is poised to make a significant impact on the global cardiac rhythm management market. The focus? A novel leadless pacemaker designed to revolutionise treatment for heart failure patients. After years of development and rigorous clinical trials, […]
Backed By Leading Investment Groups and Family Offices
